Reneuron Group (RENE)

 

RENE Share PerformanceMore

52 week high4.3700 02/10/15
52 week low2.2615 08/12/15
52 week change -1.7500 (-40.00%)
4 week volume40,957,112 31/08/16

Media for (RENE)

Presenter: Michael Hunt, CEO
04/02/2015

Latest NewsMore

Block Listing Review and Total Voting Rights

RNS Number: 5877K ReNeuron Group plc 22 September 2016 22 September 2016 AIM: RENE ReNeuron Group plc ("ReNeuron" or "the Company") Block Listing Review and Total Voting Rights ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, provides the following update in accordance with Schedule Six...

ReNeuron passes AGM resolutions

ReNeuron said that all resolutions put to shareholders at today's Annual General Meeting were duly passed. At 12:12pm: (LO...

Result of AGM

RNS Number: 0947J ReNeuron Group plc 06 September 2016 6 September 2016 AIM: RENE ReNeuron Group plc ("ReNeuron" or the "Company") Result of AGM ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, announces that all resolutions put to shareholders at today's Annual General Meeting were duly...

AGM Trading Update

RNS Number: 0052J ReNeuron Group plc 06 September 2016 6 September 2016 AIM: RENE ReNeuron Group plc ("ReNeuron" or the "Company") AGM Trading Update ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, i s pleased to provide a trading update ahead of today's Annual General Meeting. We are...

Posting of Annual Report and Notice of AGM

RNS Number: 4560G ReNeuron Group plc 05 August 2016 5 August 2016 AIM: RENE ReNeuron Group plc ("ReNeuron" or the "Company") Posting of Annual Report and Accounts and Notice of AGM ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, announces that its Annual Report and Accounts for the...

Stroke clinical data published in The Lancet

RNS Number: 1850G ReNeuron Group plc 04 August 2016 4 August 2016 AIM: RENE ReNeuron Group plc Stroke clinical data published in The Lancet Published long term Phase I data show evidence of improvements in neurological function sustained out to 24 months and good safety profile ReNeuron Group plc (the "Company") (AIM: RENE), a UK-based globa...

Publication of positive pre-clinical retinal data

RNS Number: 9275E ReNeuron Group plc 22 July 2016 AIM: RENE 22 July 2016 ReNeuron Group plc Publication of positive pre-clinical data from retinal stem cells ReNeuron's hRPC stem cells arrest visual decline in pre-clinical models of retinal degeneration, demonstrating their therapeutic potential ReNeuron Group plc (the "Company") (AIM: RENE), a UK-bas...

Directors' Interest in Shares and Share Options

RNS Number: 7721E ReNeuron Group plc 20 July 2016 20 July 2016 AIM: RENE ReNeuron Group plc Directors' Interest in Shares and Share Options ReNeuron Group plc (the "Company") (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, today announces that on 19 July 2016 , the following awards were made under the Compan...

Fundamental DataMore

EPS-0.4
Dividend yield0 %

Equity Research (RENE)

edison investment research
ReNeuron Group plc
05/08/2016
ReNeuron has announced the publication of long-term Phase I stroke clinical trial (PISCES-I) data in The Lancet. The data indicate improvements in neurological status and limb function compared with...
edison investment research
ReNeuron Group plc
27/07/2016
Investor focus is currently on the readout of ReNeuron’s Phase II stroke disability study with its CTX cells, due in Q416. Alongside this there are a number of other data readouts and progression of...
edison investment research
ReNeuron Group plc
24/03/2016
ReNeuron has treated the first patient in its US Phase I/II clinical trial with its cell therapy candidate for the blindness-causing disease retinitis pigmentosa (RP). This is a significant step...

Latest discussion posts More

  • Re: bit of info - hRPC

    http://soco.space/Uu13q2 Omg
    23-Sep-2016
    omg
  • Broker forecasts.....

    Looks like one more added? Analyst Company/Broker Recommendation Price Target Olivia Manser Stifel ...
    23-Sep-2016
    fredd1eboy
  • Re: bit of info

    just doodling Freddie :) albeit with a 'ginger' touch on emphasizing (US spelling of course) our company mol
    22-Sep-2016
    mol42

Users' HoldingsMore

Users who hold Reneuron Group also hold..
LLOYDS GRP.17%
BP13%
BARCLAYS13%
ROCKHOPPER11%
ROYAL BANK SCOT11%

Codes & Symbols

ISINGB00B0DZML60
SymbolsRENE, LSE:RENE, RENE.L, RENE:LN, LON:RENE, XLON:RENE